Newsletter Subject

[Tickers Inside] 7 Solid Gainers Over the Last 5 Sessions

From

marketinsiderspress.com

Email Address

editor@marketinsiderspress.com

Sent On

Fri, Sep 2, 2022 05:48 PM

Email Preheader Text

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please clic

Stocks with 5 days of consecutive price advances. If you cannot see this email properly, please click [here]( [marketinside...] --------------------------------------------------------------- [Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022]( [Find Out Why Experts are Comparing Lithium Mining to Last Century's Oil Boom]([aff_i?offer_...] --------------------------------------------------------------- September 2, 2022 From the desk of the Editor (5 Day Gainers Report) Dear Reader, We just identified 7 Five Day Gainers of all US Exchanges. If you are interested in any of these companies, we encourage you to do your own research and due diligence. Keep reading to see what we just uncovered... --------------------------------------------------------------- [Nevada Desert more Valuable than Wall Street or Silicon Valley?]( [170c87b0-23e...](It could be true, according to Nevada Governor Steve Sisolak. The state's desert flats contain more lithium than any other geography in the world. And with electric vehicles driving a global boom in demand for lithium-ion batteries, Nevada should be on every investor's radar. [Find Out How to Take Advantage of Nevada's Lithium Bonanza]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Pinduoduo, PDD]( Recent Analyst Action: Jiong Shao, analyst at Barclays, reiterates coverage on [Pinduoduo (PDD)](in the Consumer Goods sector with a Hold rating and a price target of $66.00 (12 hours ago). - Recent Price: $72.05 - Average Analyst Price Target: $85.41 (18.54%) - Market Cap: $89.51B [TipRanks.com]( also reports that [Pinduoduo](currently has 10 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $85.41. The target pricing ranges from a high forecast of $107.00 down to a low forecast of $66.00. [Pinduoduo (PDD)](’s last closing price was $72.05 which would put the average price target at $85.41. Here are 3rd party ratings for [PDD](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Strong Buy, Bottom 46% (137 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Market Wizard Who Accurately Predicted 2022 Market Collapse Has Shocking New Forecast]( [69616ec4-0f4...]( He predicted the 2020 crash a month before it happened… He predicted this year’s collapse back in January… And now, he’s issuing a brand-new warning – along with a unique solution. [Details here.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Centessa Pharmaceuticals, CNTA]( Recent Analyst Action: Matthew Harrison, analyst at Morgan Stanley, reiterates coverage on [Centessa Pharmaceuticals (CNTA)](in the Healthcare sector with a Sell rating and a price target of $5.00 (3 weeks ago). - Recent Price: $4.75 - Average Analyst Price Target: $6.00 (26.32%) - Market Cap: $427.99M [TipRanks.com]( also reports that [Centessa Pharmaceuticals](currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $6.00. The target pricing ranges from a high forecast of $11.00 down to a low forecast of $4.00. [Centessa Pharmaceuticals (CNTA)](’s last closing price was $4.75 which would put the average price target at $6.00. Here are 3rd party ratings for [CNTA](: - TipRanks.com: Hold - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 32% (81 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- [CareCloud, Inc., MTBC]( Recent Analyst Action: Marc Wiesenberger, analyst at B.Riley Financial, reiterates coverage on [CareCloud, Inc. (MTBC)](in the Technology sector with a Buy rating and a price target of $8.00 (4 weeks ago). - Recent Price: $3.68 - Average Analyst Price Target: $8.67 (135.60%) - Market Cap: $52.18M [TipRanks.com]( also reports that [CareCloud, Inc.](currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $8.67. The target pricing ranges from a high forecast of $13.00 down to a low forecast of $5.00. [CareCloud, Inc. (MTBC)](’s last closing price was $3.68 which would put the average price target at $8.67. Here are 3rd party ratings for [MTBC](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Neutral Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Top 35% (88 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [This "cash nozzle" could refill your income every month (up to $2,880)]( [9bab8038-2ca...](What if instead of loosing money every time you fill up at the pump… there was a way to throw the pump in reverse and fill up with cash every time you pull the handle. This "cash spout" exists in a hidden corner of the stock market. It FORCES instant payouts out of every trade. [Click here to see how it works.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Deciphera Pharmaceuticals, DCPH]( Recent Analyst Action: Tyler Van, analyst at Cowen & Co., reiterates coverage on [Deciphera Pharmaceuticals (DCPH)](in the Healthcare sector with a Buy rating and a price target of $25.00 (4 days ago). - Recent Price: $17.3 - Average Analyst Price Target: $15.78 (-8.79%) - Market Cap: $1.14B [TipRanks.com]( also reports that [Deciphera Pharmaceuticals](currently has 9 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $15.78. The target pricing ranges from a high forecast of $25.00 down to a low forecast of $8.00. [Deciphera Pharmaceuticals (DCPH)](’s last closing price was $17.3 which would put the average price target at $15.78. Here are 3rd party ratings for [DCPH](: - TipRanks.com: Hold - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 23% (59 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- [Apellis Pharmaceuticals, APLS]( Recent Analyst Action: Douglas Tsao, analyst at H.C. Wainwright, reiterates coverage on [Apellis Pharmaceuticals (APLS)](in the Healthcare sector with a Buy rating and a price target of $75.00 (1 week ago). - Recent Price: $64.41 - Average Analyst Price Target: $77.43 (20.21%) - Market Cap: $6.99B [TipRanks.com]( also reports that [Apellis Pharmaceuticals](currently has 14 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $77.43. The target pricing ranges from a high forecast of $113.00 down to a low forecast of $40.00. [Apellis Pharmaceuticals (APLS)](’s last closing price was $64.41 which would put the average price target at $77.43. Here are 3rd party ratings for [APLS](: - TipRanks.com: Strong Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 23% (59 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [WARNING: Do you invest with these banks?]( [6eeab3e8-581...]( Take a close look at the investment banks above. Because if you have stocks with any of these brokerages... These new political developments WILL affect you. [If you invest with any of these brokerage firms, click here to see how to protect your portfolio from this new conflict.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [RVL Pharmaceuticals, RVLP]( Recent Analyst Action: Douglas Tsao, analyst at H.C. Wainwright, reiterates coverage on [RVL Pharmaceuticals (RVLP)](in the Healthcare sector with a Buy rating and a price target of $5.00 (2 days ago). - Recent Price: $2.4 - Average Analyst Price Target: $5.00 (108.33%) - Market Cap: $230.03M [TipRanks.com]( also reports that [RVL Pharmaceuticals](currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $5.00. The target pricing ranges from a high forecast of $5.00 down to a low forecast of $5.00. [RVL Pharmaceuticals (RVLP)](’s last closing price was $2.4 which would put the average price target at $5.00. Here are 3rd party ratings for [RVLP](: - TipRanks.com: Moderate Buy - TradingView.com: Strong Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 32% (81 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- [DXC Technology, DXC]( Recent Analyst Action: Bryan Bergin, analyst at Cowen & Co., reiterates coverage on [DXC Technology (DXC)](in the Technology sector with a Buy rating and a price target of $37.00 (2 weeks ago). - Recent Price: $27.495 - Average Analyst Price Target: n/a (34.13%) - Market Cap: $6.14B [TipRanks.com]( also reports that [DXC Technology](currently has 9 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $36.88. The target pricing ranges from a high forecast of $48.00 down to a low forecast of $30.00. [DXC Technology (DXC)](’s last closing price was $27.495 which would put the average price target at $36.88. Here are 3rd party ratings for [DXC](: - TipRanks.com: Moderate Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong sell - Zacks.com: Hold, Bottom 43% (144 out of 252) [Click here for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- [Amazon is hiding this income secret from you]( [edee8dcc-554...](Countless people own Amazon stock. Yet most are not collecting income from their shares. That's because Amazon doesn't officially pay a dividend… but there's a [little-known way to collect weekly income from the stock.]( And it can deliver reliable weekly payouts of $185... $297 or more. It's not your fault if you haven't used this income secret before. For one, Amazon doesn't advertise it. For everything you need to know... [click here to start collecting this income ASAP.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- And there you have it--7 Five Day Gainers of all US Exchanges. To Your Financial Future, The Editor, MarketInsidersPress.com Market Insider Press Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. MarketInsidersPress.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane | Mooresville NC | 28115 Sandpiper Marketing Group, LLC | 165 Lockerbie Lane | Moorsville | North Carolina | 28115 | United States | 8458030954 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software

Marketing emails from marketinsiderspress.com

View More
Sent On

09/05/2024

Sent On

09/05/2024

Sent On

09/05/2024

Sent On

08/05/2024

Sent On

08/05/2024

Sent On

08/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.